Bioprothesen, mechanische Klappen, Bio-engineered-Klappen – Update 2013

Abstract

Significant changes have been seen in surgical access and substitutes of heart valve patients, recently. The „Ross Procedure“ has lost some attractiveness, and minimal access as well as interventional techniques are becoming more often used. Sutureless aortic valves safe time during open heart surgery and first tissue engineered valve have been explored clinically.

• Literatur

• 1 Beckmann A, Funkat AK, Lewandowski J et al. Cardiac Surgery in Germany during 2012: A Report on Behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg 2013; Dec 9. [Epub ahead of print] DOI: 10.1055/s-0033-1361953
• 2 Guyton RA. The Placement of Aortic Transcatheter Valve (PARTNER) trial: the surgeon's perspective: celebration and concern. Circulation 2012; 125: 3237-3239
• 3 Ielasi A, Latib A, Tespili M. Current and new-generation transcatheter aortic valve devices: an update on emerging technologies. Expert Rev Cardiovasc Ther 2013; 11: 1393-1405
• 4 Yap KH, Murphy R, Devbhandari M et al. Aortic valve replacement: is porcine or bovine valve better?. Interact Cardiovasc Thorac Surg 2013; 16: 361-373
• 5 Mark DB, Mentz RJ. The Placement of Aortic Transcatheter Valve (PARTNER) trial: a health economic and policy perspective. Circulation 2012; 125: 3243-3245
• 6 Reece TB, Welke KF, O'Brien S et al. Rethinking the Ross Procedure in Adults. Ann Thorac Surg 2013; 13: 1646-1649
• 7 Rippel RA, Ghanbari H, Seifalian AM. Tissue-engineered heart valve: future of cardiac surgery. World J Surg 2012; 36: 1581-1591
• 8 Bianchi G, Solinas M, Bevilacqua S et al. Are bioprostheses associated with better outcome than mechanical valves in patients with chronic kidney disease requiring dialysis who undergo valve surgery?. Interact Cardiovasc Thorac Surg 2012; 15: 473-483
• 9 Okonta KE, Adamu YB. What size of vegetation is an indication for surgery in endocarditis?. Interact Cardiovasc Thorac Surg 2012; 15: 1052-1056
• 10 Que YA, Moreillon P. Infective endocarditis. Nat Rev Cardiol 2011; 8: 322-336
• 11 Okada K, Okita Y. Surgical treatment for aortic periannular abscess/pseudoaneurysm caused by infective endocarditis. Gen Thorac Cardiovasc Surg 2013; 61: 175-181
• 12 Elahi M, Asopa S, Khan J. The right choice of prosthesis for patients undergoing aortic valve surgery: searching the truth. Acute Card Care 2007; 9: 77-81
• 13 Jamieson WR, Cartier PC, Allard M et al. Surgical management of valvular heart disease 2004. Can J Cardiol 2004; 20: 7E-120E
• 14 Ross D, Yacoub MH. Homograft replacement of the aortic valve. A critical review. Prog Cardiovasc Dis 1969; 11: 275-293
• 15 El-Hamamsy I, Eryigit Z, Stevens LM et al. Long-term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomised controlled trial. Lancet 2010; 376: 524-531
• 16 Lichtenberg A, Cebotari S, Tudorache I et al. Biological scaffolds for heart valve tissue engineering. Methods Mol Med 2007; 140: 309-317
• 17 Simon P, Kasimir MT, Seebacher G et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg 2003; 23: 1002-1006 ; discussion 1006
• 18 Cebotari S, Lichtenberg A, Tudorache I et al. Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 2006; 114: I132-137
• 19 da Costa FD, Dohmen PM, Duarte D et al. Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation. Eur J Cardiothorac Surg 2005; 27: 572-528
• 20 Cebotari S, Tudorache I, Ciubotaru A et al. Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: early report. Circulation 2011; 124: 115-123
• 21 Baraki H, Tudorache I, Braun M et al. Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model. Biomaterials 2009; 30: 6240-6246
• 22 Cremer J, Mügge A, Wittwer T et al. Early angiographic results after revascularization by minimally invasive direct coronary artery bypass (MIDCAB). Eur J Cardiothorac Surg 1999; 15: 383-387
• 23 Arcidi Jr JM, Rodriguez E, Elbeery JR et al. Fifteen-year experience with minimally invasive approach for reoperations involving the mitral valve. J Thorac Cardiovasc Surg 2012; 143: 1062-1068
• 24 Schmitto JD, Mohr FW, Cohn LH. Minimally invasive aortic valve replacement: how does this perform in high-risk patients?. Curr Opin Cardiol 2011; 26: 118-122
• 25 Shrestha M, Timm R, Höffler K et al. Minimally invasive aortic valve replacement with self-anchoring Perceval valve. J Heart Valve Dis 2013; 22: 230-235
• 26 Martens S, Ploss A, Sirat S et al. Sutureless aortic valve replacement with the 3f Enable aortic bioprosthesis. Ann Thorac Surg 2009; 87: 1914-1917
• 27 Flameng W, Laborde F, Haverich A. Sutureless Perceval S aortic valve replacement: a multicenter, prospective pilot trial. J Heart Valve Dis 2009; 18: 698-702
• 28 Kocher AA, Laufer G, Haverich A et al. One-year outcomes of the Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve (TRITON) trial: a prospective multicenter study of rapid-deployment aortic valve replacement with the EDWARDS INTUITY Valve System. J Thorac Cardiovasc Surg 2013; 145: 110-115
• 29 Santarpino G, Pfeiffer S, Concistré G et al. The Perceval S aortic valve has the potential of shortening surgical time: does it also result in improved outcome?. Ann Thorac Surg 2013; 96: 77-81